Literature DB >> 18818883

The technological transformation of patient-driven human immunology research.

Helen C Su1.   

Abstract

New scientific technologies applied to patients with rare diseases are facilitating discoveries about how the human immune system is regulated at the molecular level. Studies of patients with autoimmune lymphoproliferative syndrome (ALPS) or caspase-8 deficiency state (CEDS) demonstrated the ability of gene expression microarray analyses and small interfering RNAs (siRNA) to establish the physiologically important roles of NRAS, caspase-10, and caspase-8 for normal lymphocyte apoptosis and activation. The advent of genomics technologies such as next generation sequencing will complement these and more traditional approaches. These advances are anticipated to accelerate the pace of new discoveries in patients with immunological disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18818883     DOI: 10.1007/s12026-008-8062-9

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  14 in total

Review 1.  Next-generation sequencing transforms today's biology.

Authors:  Stephan C Schuster
Journal:  Nat Methods       Date:  2007-12-19       Impact factor: 28.547

2.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

Authors:  J Drappa; A K Vaishnaw; K E Sullivan; J L Chu; K B Elkon
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

3.  Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.

Authors:  D A Martin; L Zheng; R M Siegel; B Huang; G H Fisher; J Wang; C E Jackson; J M Puck; J Dale; S E Straus; M E Peter; P H Krammer; S Fesik; M J Lenardo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.

Authors:  J Wang; L Zheng; A Lobito; F K Chan; J Dale; M Sneller; X Yao; J M Puck; S E Straus; M J Lenardo
Journal:  Cell       Date:  1999-07-09       Impact factor: 41.582

5.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

6.  The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.

Authors:  A J Infante; H A Britton; T DeNapoli; L A Middelton; M J Lenardo; C E Jackson; J Wang; T Fleisher; S E Straus; J M Puck
Journal:  J Pediatr       Date:  1998-11       Impact factor: 4.406

7.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 8.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

9.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.

Authors:  Hyung J Chun; Lixin Zheng; Manzoor Ahmad; Jin Wang; Christina K Speirs; Richard M Siegel; Janet K Dale; Jennifer Puck; Joie Davis; Craig G Hall; Suzanne Skoda-Smith; T Prescott Atkinson; Stephen E Straus; Michael J Lenardo
Journal:  Nature       Date:  2002-09-26       Impact factor: 49.962

10.  NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

Authors:  João B Oliveira; Nicolas Bidère; Julie E Niemela; Lixin Zheng; Keiko Sakai; Cynthia P Nix; Robert L Danner; Jennifer Barb; Peter J Munson; Jennifer M Puck; Janet Dale; Stephen E Straus; Thomas A Fleisher; Michael J Lenardo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

View more
  1 in total

Review 1.  Monogenic autoimmune diseases: insights into self-tolerance.

Authors:  Maureen A Su; Mark S Anderson
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.